Clinical Laserthermia Systems AB (publ)

Stockholm Stock Exchange CLS-B.ST

Clinical Laserthermia Systems AB (publ) Price to Sales Ratio (P/S) on January 14, 2025: 6.87

Clinical Laserthermia Systems AB (publ) Price to Sales Ratio (P/S) is 6.87 on January 14, 2025, a -83.01% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.
  • Clinical Laserthermia Systems AB (publ) 52-week high Price to Sales Ratio (P/S) is 4,060.63 on April 19, 2024, which is 59,034.92% above the current Price to Sales Ratio (P/S).
  • Clinical Laserthermia Systems AB (publ) 52-week low Price to Sales Ratio (P/S) is 6.16 on August 06, 2024, which is -10.30% below the current Price to Sales Ratio (P/S).
  • Clinical Laserthermia Systems AB (publ) average Price to Sales Ratio (P/S) for the last 52 weeks is 29.89.
Key data
Date Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield
Market news
Stockholm Stock Exchange: CLS-B.ST

Clinical Laserthermia Systems AB (publ)

CEO Mr. Dan Johansson Mogren
IPO Date April 16, 2009
Location Sweden
Headquarters Building 405
Employees 17
Sector Health Care
Industries
Pharmaceuticals Biotechnology Clinical Trials
Description

Clinical Laserthermia Systems AB (publ) develops treatment tools for diseased tissue under the TRANBERG brand in Sweden. The company offers TRANBERG, a thermal therapy system designed to deliver laser energy to heat the target tissue. It also provides mobile laser unit, a controlling component with a wavelength of 1064 nanometers provides multiple options to control treatment. In addition, the company offers various gauge laser applicators, as well as provides temperature and treatment monitoring devices. Clinical Laserthermia Systems AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.

Similar companies

CANTA.ST

Cantargia AB (publ)

USD 0.15

0.09%

StockViz Staff

January 15, 2025

Any question? Send us an email